Orange Book product · Brand (NDA)
OZURDEX
DEXAMETHASONE
At a glance
Jun 17, 2009
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jun 17, 2009
17 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
DEXAMETHASONE
Strength
0.7MG
Dosage form
IMPLANT
Route
INTRAVITREAL
TE code
Not listed
Application
NDA 022315
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2018DEXTENZABrand (NDA)
NDA 208742 · OCULAR THERAPEUTIX
- 2018DEXYCU KITBrand (NDA)
NDA 208912 · EYEPOINT PHARMS
- —DECASPRAYBrand (NDA)
NDA 012731 · MERCK
- —DECADRONBrand (NDA)
NDA 012376 · MERCK
- —HEXADROLBrand (NDA)
NDA 012674 · ASPEN GLOBAL INC
- —DECADERMBrand (NDA)
NDA 013538 · MERCK
- —MAXIDEXBrand (NDA)
NDA 013422 · HARROW EYE
- —DECADRONBrand (NDA)
NDA 011664 · MERCK
- 2024DEXAMETHASONEGeneric (ANDA)
ANDA 218372 · COREPHARMA
- 2023DEXAMETHASONEGeneric (ANDA)
ANDA 215604 · NOVITIUM PHARMA
- 2023DEXAMETHASONEGeneric (ANDA)
ANDA 217695 · APOTEX
- 2023DEXAMETHASONEGeneric (ANDA)
ANDA 217696 · NOVITIUM PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
